Latest Breaking News On - Ospa igg - Page 1 : comparemela.com

Lyme disease vaccine candidate: Valneva and Pfizer report more positive Phase 2 data

Lyme disease vaccine candidate: Valneva and Pfizer report more positive Phase 2 data
outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesKathrinu jansenJuan carlos jaramilloDrug administrationHead of vaccine research development at pfizerOspa iggChief medical officerSenior vice presidentVaccine researchNorth americaFast track

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

• Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 • Sub-analysis compared the immunogenicity of VLA15 in adults 18-65 years of age after administration of two or three primary series doses • Stronger immune response observed in adult participants who received three priming doses vs. two priming doses; pediatric study ongoing with initial data expected in 1H2022 • Three-dose priming schedule selected for use in adults moving forward

United statesNew yorkKathrinu jansenJuan carlos jaramilloPfizer incDrug administrationJournal of public healthHead of vaccine research development at pfizerEuronext parisOspa iggChief medical officerSenior vice presidentVaccine researchNorth americaFast trackPublic health

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate – Valneva

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate – Valneva
valneva.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from valneva.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkKathrinu jansenJuan carlos jaramilloJoshua drummDrug administrationJournal of public healthHead of vaccine research development at pfizerExchange commissionPfizer incVp global communications european investor relationsEuronext parisOspa iggChief medical officerSenior vice presidentVaccine research

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

04.02.2022 - Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022Sub-analysis compared the immunogenicity of VLA15 in adults 18-65 years of age after administration of two or three primary series dosesStronger immune response . Seite 1

New yorkUnited statesPfizer incEuronext parisOspa igg